Sacubitril-valsartan cost-effective for treating reduced ejection fraction heart failure

(American College of Physicians) Sacubitril-valsartan is reasonably cost effective compared to widely-used therapies for reducing mortality and morbidity in patients with reduced ejection fraction heart failure. The findings are published in Annals of Internal Medicine.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news